Daraxonrasib pill makes pancreatic tumours undetectable in one in 12 patients
The KRAS inhibitor, taken with chemotherapy, stopped tumour growth in nearly all of 61 patients with advanced pancreatic cancer.
A daily pill called daraxonrasib, taken alongside chemotherapy, made cancer undetectable on scans in one in 12 patients in early trials.
During the trial, tumours stopped growing in 90% of patients, just over 60% had tumours shrink or disappear, and about 8% had tumours that became undetectable on CT scans. A year after starting treatment, 76.6% of patients were alive, compared with usually 40-45% of patients given chemotherapy alone.
Doctors have said the pill cannot yet be considered a cure and that they do not know how long it can keep the disease at bay. Patients were followed for a year and a half on average, and some did not see the cancer return during this period. Longer studies will be conducted to see whether any of the cancers can be put into remission.
Daraxonrasib is a KRAS inhibitor that locks on to and shuts off mutations found in most pancreatic cancers, which drive tumour growth. Michelle Mitchell, chief executive of Cancer Research UK, called it "the biggest leap forward we've seen in decades for pancreatic cancer patients" but said more trials are needed before the treatment can be assessed for use on the NHS.
Key facts
- Cancer became undetectable on scans in one in 12 patients given daraxonrasib with chemotherapy.
- Tumours stopped growing in almost all of the 61 participants.
- A year after starting treatment, 76.6% of patients were alive.
Three perspectives
Neutral
A daily pill called daraxonrasib, taken with chemotherapy, made cancer undetectable in one in 12 patients with advanced pancreatic cancer in early trials.
Positive
Tumours stopped growing in almost all of the 61 participants, and the treatment may offer patients more time.
Negative
Doctors say the pill cannot yet be considered a cure and it is not known how long it can keep the disease at bay.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.
